Trial Profile
A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 04 Nov 2020 Status changed from recruiting to completed.
- 15 Apr 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 15 Apr 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.